Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Business News, In Brief

Executive Summary

Companies talk drug launches and pipelines during first quarter earnings calls in May; with some having more success than others.


Related Content

McKesson/Celesio Deal Targets Generics Purchasing Synergies
Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch
IBS Trials Should Gauge Efficacy In Maintenance And Retreatment, FDA Says
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Cardinal’s China Operations Running “Ahead Of Plan,” More Expansion Ahead
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts